DE3885317T2 - Makromolekulare Platin-Antitumorverbindungen. - Google Patents

Makromolekulare Platin-Antitumorverbindungen.

Info

Publication number
DE3885317T2
DE3885317T2 DE88301410T DE3885317T DE3885317T2 DE 3885317 T2 DE3885317 T2 DE 3885317T2 DE 88301410 T DE88301410 T DE 88301410T DE 3885317 T DE3885317 T DE 3885317T DE 3885317 T2 DE3885317 T2 DE 3885317T2
Authority
DE
Germany
Prior art keywords
tumor compounds
platinum anti
macromolecular
tumor
macromolecular platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE88301410T
Other languages
English (en)
Other versions
DE3885317D1 (de
Inventor
Anthony J Serino
Geoffrey W Henson
David A Schwartz
Donald H Picker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Matthey Inc
Original Assignee
Johnson Matthey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Inc filed Critical Johnson Matthey Inc
Publication of DE3885317D1 publication Critical patent/DE3885317D1/de
Application granted granted Critical
Publication of DE3885317T2 publication Critical patent/DE3885317T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Insulating Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE88301410T 1987-02-25 1988-02-19 Makromolekulare Platin-Antitumorverbindungen. Expired - Fee Related DE3885317T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/018,715 US4793986A (en) 1987-02-25 1987-02-25 Macromolecular platinum antitumor compounds

Publications (2)

Publication Number Publication Date
DE3885317D1 DE3885317D1 (de) 1993-12-09
DE3885317T2 true DE3885317T2 (de) 1994-03-03

Family

ID=21789419

Family Applications (1)

Application Number Title Priority Date Filing Date
DE88301410T Expired - Fee Related DE3885317T2 (de) 1987-02-25 1988-02-19 Makromolekulare Platin-Antitumorverbindungen.

Country Status (12)

Country Link
US (1) US4793986A (de)
EP (1) EP0280474B1 (de)
JP (1) JPS63284134A (de)
AT (1) ATE96679T1 (de)
AU (1) AU596774B2 (de)
CA (1) CA1305665C (de)
DE (1) DE3885317T2 (de)
DK (1) DK96588A (de)
IE (1) IE63003B1 (de)
NO (1) NO175964C (de)
NZ (1) NZ223549A (de)
ZA (1) ZA881077B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952676A (en) * 1984-06-27 1990-08-28 Johnson Matthey Plc Monoclonal antibody-platinum co-ordination compound complex
US4956454A (en) * 1984-06-27 1990-09-11 Johnson Matthey Plc Monoclonal antibody - platinum co-ordination compound complex
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US4931553A (en) * 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
SU1685944A1 (ru) * 1988-06-06 1991-10-23 Институт Физической Химии Им.Л.В.Писаржевского Способ получени комплексного соединени платины (II) с высокомолекул рной н-ДНК из селезенки крупного рогатого скота марки А, обладающего противоопухолевой активностью
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
AU648022B2 (en) * 1989-03-14 1994-04-14 Bionebraska, Inc. Monoclonal antibodies for metallic cations on small molecules
US5639624A (en) * 1989-03-14 1997-06-17 Board Of Regents Of The University Of Nebraska Monoclonal antibodies specific for metallic cations and method therefor
US5972656A (en) * 1989-03-14 1999-10-26 Bionebraska, Inc. Mercury binding polypeptides and nucleotides coding therefore
DE69112684T2 (de) * 1990-04-06 1996-02-01 Univ Tulane LHRH-Analoge.
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
KR960704921A (ko) * 1993-10-04 1996-10-09 알렝 갈로샤 세로토닌 전달을 조절하는 화합물 및 이의 진단과 치료적 이용
EP0692252B1 (de) * 1994-06-14 2001-04-04 "Raffinerie Tirlemontoise", société anonyme: Verwendung einer Zusammensetzung enthaltend Inulin oder Oligofructose als Antikrebsmittel
AU2701395A (en) * 1994-06-27 1996-01-19 General Hospital Corporation, The Graft co-polymer adducts of platinum (ii) compounds
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US6111079A (en) * 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
JP2002508758A (ja) * 1997-06-12 2002-03-19 エムエル・ラボラトリーズ・パブリック・リミテッド・カンパニー 生物的に活性な材料
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU2762101A (en) * 2000-01-04 2001-07-16 Access Pharmaceuticals, Inc. N,o-amidomalonate platinum complexes
JP2004501869A (ja) 2000-03-22 2004-01-22 ソルリンク・インコーポレイテッド ヒドラジンベース及びカルボニルベースの二官能性架橋剤
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US20030082102A1 (en) * 2001-06-25 2003-05-01 Court Wayne S. Radioactive platinum complexes for cancer treatment
DE60323936D1 (de) 2002-01-14 2008-11-20 Gen Hospital Corp Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
AU2003254023A1 (en) 2002-07-19 2004-02-09 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
CA2537993C (en) 2003-09-05 2012-08-28 The General Hospital Corporation Dual phase drug release system
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
EP1745802A1 (de) * 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Verfahren zur Konjugierung therapeutischer Verbindungen an zellgezielten Gruppen über Metallkomplexen
WO2007126078A1 (ja) * 2006-04-27 2007-11-08 Onecell Inc. ヌクレオチド－遷移金属錯体触媒
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US20080300389A1 (en) * 2007-06-04 2008-12-04 Yang David J Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
PE20100746A1 (es) 2008-12-10 2010-11-04 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
NL2020121B1 (en) * 2017-12-19 2019-06-26 Linxis B V Platinum-based functional moieties for preparing cell targeting conjugates
NL2020120B1 (en) * 2017-12-19 2019-06-26 Linxis B V Methods for preparing cell targeting conjugates and conjugates obtainable by said methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4385046A (en) * 1980-12-15 1983-05-24 Minnesota Mining And Manufacturing Company Diagnostic radio-labeled polysaccharide derivatives
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
IL66338A (en) * 1982-07-15 1986-03-31 Yeda Res & Dev Anti-cancer drugs comprising platinum complexed antitumor immunoglobulins
US4584392A (en) * 1982-11-10 1986-04-22 Inco Alloys International, Inc. Platinum and palladium complexes
IL67789A (en) * 1983-01-31 1986-09-30 Yissum Res Dev Co Amino-substituted malonato platinum(ii)complexes and method for their preparation
US4673754A (en) * 1983-10-14 1987-06-16 Inco Alloys International, Inc. Platinum and palladium complexes
EP0167310B1 (de) * 1984-06-27 1991-05-29 Johnson Matthey Public Limited Company Platinkoordinationsverbindungen
IL73972A0 (en) * 1984-12-31 1985-03-31 Yeda Res & Dev Agents based on platinum compounds

Also Published As

Publication number Publication date
NO175964C (no) 1995-01-11
AU1213588A (en) 1988-09-01
AU596774B2 (en) 1990-05-10
NO175964B (no) 1994-10-03
JPS63284134A (ja) 1988-11-21
EP0280474A3 (en) 1990-01-31
NO880705L (no) 1988-08-26
EP0280474A2 (de) 1988-08-31
DE3885317D1 (de) 1993-12-09
US4793986A (en) 1988-12-27
DK96588A (da) 1988-08-26
IE880498L (en) 1988-08-25
ZA881077B (en) 1988-08-11
DK96588D0 (da) 1988-02-24
EP0280474B1 (de) 1993-11-03
ATE96679T1 (de) 1993-11-15
NO880705D0 (no) 1988-02-17
CA1305665C (en) 1992-07-28
NZ223549A (en) 1989-10-27
IE63003B1 (en) 1995-03-08

Similar Documents

Publication Publication Date Title
DE3885317T2 (de) Makromolekulare Platin-Antitumorverbindungen.
NO901986L (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
GR890100846A (el) Μεθοδος μετατροπης κυτταρικης διαφοροποιησης και λειτουργιας καισυνθεσεις της.
DK15589D0 (da) Kemiske forbindelser
FR2326192A1 (fr) Nouvelles pyrimidones, leur procede de preparation et leur application therapeutique
EP0200024A3 (en) 3-cyano-pyridines, process for their preparation and their pharmaceutical use
PH18031A (en) Immunoglobulin conjugates,process for preparing them and pharmaceutical composition containing the same
FI810559L (fi) Nya 3,4,5-trihydroxipiperidinderivat foerfaranden foer deras framstaellning och deras anvaendning som laekemedel samt i djurnaering
ATE237338T1 (de) Allogene parakrine cytokine tumor impfstoffe
IL58103A (en) Sila-substituted 1,4-dihydropyridine derivatives,their production and pharmaceutical compositions containing them
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
PT81093B (pt) Processo para a preparacao de uma composicao terapeutica para tratamento de um tumor
DK258283A (da) Fremgangsmaade til fremstilling af et heparinfragment med en molekylvaegt paa 2000 til 5500 og kovalent bundet til antithrombin iii
ES472640A1 (es) Procedimiento para preparar seudotrisacaridos
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
DK398483A (da) Substituerede tert.butanol-derivater, fremgangsmaader til fremstilling deraf samt antimykotiske midler indeholdende disse forbindelser
ATE69220T1 (de) Sechsgliedrige heterocyclische derivate von n'substituiertenn,n'-diacylhydrazinen.
NO842345L (no) Heksahydropyrrolo(2,1-a)isoquinolin-derivater.
DK0457215T3 (da) 3-deamino-4-desoxy-4-amino-8-fluoranthracycliner samt fremgangsmåder til fremstilling deraf
ATE87314T1 (de) Platin-arzneimittel.
SU568574A1 (ru) Прижимной механизм вертикального двухленточного конвейера
IT8620798A0 (it) Derivati triazinici di piperidinilammidine atti all'impiego come stabilizzanti per polimeri sintetici.
ES474052A1 (es) Procedimiento para la obtencion de 1,4-dihidropiridazinas 1-n-sustituidas.
ES2061602T3 (es) Polimeros acrilicos imidizados y procedimiento para su preparacion.
NL190506B (nl) Werkwijze voor de bereiding van veevoeder of een bestaand deel daarvan door concentreren van de uitgangsstoffen, verlagen van de ph en toevoegen van conserveermiddel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee